Based on these observations, compounds that target and inhibit T cell activation and proliferation, for example by interfering with the CD28–CD80/CD86 co-stimulatory pathway, represent promising drug candidates for the treatment of IBD. Here, CD28 is linked to inflammatory bowel disease.